Core Viewpoint - Weigao Blood Products (603014) experienced a decline of 3.98% in stock price, with a trading volume turnover rate of 32.30% and a total transaction amount of 559 million yuan, indicating significant market activity and selling pressure [2][3]. Trading Activity - The stock was listed on the Shanghai Stock Exchange's "Dragon and Tiger List" due to its high turnover rate, with a net selling amount of 17.96 million yuan from brokerage seats [2]. - The top five brokerage seats accounted for a total transaction amount of 131 million yuan, with buying transactions amounting to 56.41 million yuan and selling transactions totaling 74.37 million yuan, resulting in a net selling of 17.96 million yuan [2]. - The largest buying brokerage was Zheshang Securities, with a purchase amount of 22.53 million yuan, while the largest selling brokerage was Huatai Securities, with a selling amount of 23.00 million yuan [2][3]. Recent Performance - Over the past six months, the stock has appeared on the "Dragon and Tiger List" five times, with an average price drop of 4.24% the day after being listed and an average decline of 6.30% over the following five days [3]. - On the day of the report, the stock saw a net outflow of 66.82 million yuan in main funds, with large orders contributing to a net outflow of 41.33 million yuan and 25.49 million yuan respectively. However, there was a net inflow of 119 million yuan in the past five days [3]. Financial Performance - The company reported its third-quarter results on October 31, showing a total revenue of 2.736 billion yuan for the first three quarters, representing a year-on-year growth of 3.45%. The net profit reached 341 million yuan, reflecting a year-on-year increase of 7.92% [3].
威高血净11月5日龙虎榜数据